What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?

被引：19
|
作者：
Liu, Joyce F. [1 ]
Matulonis, Ursula A. [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA
来源：
CURRENT ONCOLOGY REPORTS | 2016年 / 18卷 / 05期
关键词：
Ovarian cancer; PARP inhibitors; Olaparib; Veliparib; Rucaparib; Niraparib; RECURRENT EPITHELIAL OVARIAN; OLAPARIB MAINTENANCE THERAPY; RECOMBINATION DNA-REPAIR; NEGATIVE BREAST-CANCER; HOMOLOGOUS RECOMBINATION; POLY(ADP-RIBOSE) POLYMERASE; FALLOPIAN-TUBE; DOWN-REGULATION; PHASE-II; PRIMARY PERITONEAL;
D O I：
10.1007/s11912-016-0515-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Poly-ADP-ribose polymerase (PARP) inhibitors have been one of the most exciting developments in the treatment of ovarian cancer in recent years. Demonstration of anticancer activity has led to the European Medicines Agency (EMA) approval of the PARP inhibitor (PARPi) olaparib as maintenance therapy in women with BRCA-mutated (BRCAm) ovarian cancer with platinum-sensitive recurrence following response to platinum therapy and the US Food and Drug Administration (US FDA) approval of olaparib in relapsed germline BRCA-mutated (gBRCAm) ovarian cancer in women who have received at least three prior chemotherapy treatments, both occurring in 2014. Additional trials are underway or awaiting final analysis with olaparib, other PARPis, and PARPi combinations to further elucidate the activity of these drugs in various clinical settings. This review will focus on the current clinical experience and ongoing trials with PARPis in ovarian cancer.
引用
收藏
页数：9
相关论文
共 50 条
  • [41] Recurrent ovarian cancer: maintenance treatment with PARP inhibitors in clinical practice
    Oliveira, Ines
    Mira, Beatriz
    Fragoso, Sofia
    Opiniao, Ana
    Cardoso, Catarina
    Guimaraes, Antonio
    Vaz, Fatima
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S259 - S260
  • [42] PARP Inhibitors for Treatment of Ovarian Cancer: The Downside of Good Intentions.
    Bellio, Chiara
    Foster, Rosemary
    Growdon, Whitfield B.
    Rueda, Bo R.
    REPRODUCTIVE SCIENCES, 2016, 23 : 179A - 179A
  • [43] PARP inhibitors in cancer treatment
    Calvert, H.
    Plummer, E. R.
    Curtin, N. J.
    Edmondson, R.
    Drew, Y.
    EJC SUPPLEMENTS, 2008, 6 (12): : 80 - 80
  • [44] The Role of PARP Inhibitors in the Treatment of Ovarian Carcinomas
    Tinker, Anna V.
    Gelmon, Karen
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (25) : 3770 - 3774
  • [45] Making the best of PARP inhibitors in ovarian cancer
    Susana Banerjee
    Stan B. Kaye
    Alan Ashworth
    Nature Reviews Clinical Oncology, 2010, 7 : 508 - 519
  • [46] The Current Landscape of PARP Inhibitors in Ovarian Cancer
    Gunderson, Camille C.
    Erickson, Britt K.
    Buechel, Megan E.
    Moore, Kathleen N.
    CURRENT OBSTETRICS AND GYNECOLOGY REPORTS, 2018, 7 (01): : 20 - 27
  • [47] Making the best of PARP inhibitors in ovarian cancer
    Banerjee, Susana
    Kaye, Stan B.
    Ashworth, Alan
    NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (09) : 508 - 519
  • [48] The current status of PARP inhibitors in ovarian cancer
    McLachlan, Jennifer
    George, Angela
    Banerjee, Susana
    TUMORI JOURNAL, 2016, 102 (05): : 433 - 440
  • [49] PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca"
    Boussios, Stergios
    Karathanasi, Afroditi
    Cooke, Deirdre
    Neille, Cherie
    Sadauskaite, Agne
    Moschetta, Michele
    Zakynthinakis-Kyriakou, Nikolaos
    Pavlidis, Nicholas
    DIAGNOSTICS, 2019, 9 (02)
  • [50] Therapeutic applications of PARP inhibitors in ovarian cancer
    Xie, Hongyu
    Wang, Wenjie
    Xia, Bairong
    Jin, Weilin
    Lou, Ge
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 127
12345